Objectives Anti-citrullinated protein antibodies (ACPA) have a low prevalence in juvenile idiopathic arthritis (JIA) patients. Recently, autoantibodies recognizing carbamylated proteins (anti-CarP) were observed in rheumatoid arthritis (RA) patients and were reported to be associated with a more severe clinical course in ACPA negative RA. We investigated the presence of anti-CarP antibodies in JIA patients and their relation to ACPA and IgM-rheumatoid factor (IgM-RF).
Anticarbamylated protein (anti-CarP) antibodies are present in sera of juvenile idiopathic arthritis (JIA) patients
Introduction
Juvenile idiopathic arthritis (JIA) is a heterogeneous group of chronic arthritides that starts before the age of 16. Different categories according to ILAR criteria are discerned [1] and the diagnosis is made clinically after exclusion of other causes of arthritis. Prognosis is currently largely unpredictable, except for rheumatoid factor (RF)-positive individuals. Reaching sustained remission is still scarce [2] although treatment options have improved with biologicals [3] , resulting in better outcome. [4] Research to identify markers predicting disease flares is ongoing, [5] [6] [7] but markers that predict severe disease are currently lacking.
The discovery of anti-citrullinated protein antibodies (ACPA), often detected using assays based on cyclic-citrullinated peptides (CCP), has contributed substantially to the understanding of rheumatoid arthritis (RA). [8] The presence of ACPA is now part of the 2010 EULAR/ACR criteria for RA. ACPA-positive RA patients have generally more severe disease courses with increased joint destruction. [9] Incidence rates for ACPA-positivity, usually detected by a CCP-assay, in JIA are low (2-5%). [10] [11] [12] [13] The presence of ACPA in JIA is merely confined to the polyarticular IgM-RF positive JIA category that resembles RA.
Recently, anti-carbamylated protein antibodies (anti-CarP) were described as a novel serological marker. [14] [15] [16] These antibodies are directed against proteins that have been modified by a post-translational modification named carbamylation. The physiological process of carbamylation increases during inflammation. In carbamylated proteins lysines are converted into homocitrullines. Anti-CarP antibodies were detected in sera of approximately 45% of RA patients and importantly in sera of 16-20% ACPAnegative RA patients, in comparison to less than 3% in healthy controls. [15, 17, 18] Within the ACPA-negative patients the presence of anti-CarP antibodies was associated with more severe radiographic progression. [15] Therefore anti-CarP antibodies could serve as a new prognostic marker in ACPA-negative RA patients [19] Since the majority of JIA patients are ACPA-negative we analyzed whether anti-CarP antibodies can be detected in sera of JIA patients and whether their occurrence correlates with the presence of ACPA and/or IgM-RF.
Materials and methods

Sample collection
JIA patients from three Dutch sources were included. The correlation between anti-CarP antibodies and time in active disease as a measure of severity was investigated in the second cohort. The correlation between anti-CarP antibodies and ACRpedi30 response [23] (at least 30% improvement from baseline in 3 of 6 variables in the core set, with no more than 1 of the remaining variables worsening by >30%. Core set variables are 1) physician global assessment of disease activity; 2) parent/patient assessment of overall well-being; 3) functional ability; 4) number of joints with active arthritis; 5) number of joints with limited range of motion; and 6) erythrocyte sedimentation rate) after start of a biological was determined in the group from the ABC register. 
Statistical Analysis
Statistical analyses were performed with SPSS 17,0. Fisher's exact test was used for testing the significance of differences between the percentages anti-CarP-positive and -negative patients. Pearson's chi square and student's t-test were used for identifying differences in time-in-active-disease [20] and ACRpedi30 response [23] between anti-CarP-positive and negative patients. Binary logistic regression with sensitivity analysis was used to test the interaction between age and the presence of anti-CarP antibodies. A p-value of less than 0,05 was considered statistically significant.
Results
Anti-CarP antibodies are present in JIA patients
All sera were tested for the presence of anti-CarP antibodies using Ca-FCS and Ca-Fib as antigens. In the total JIA cohort 8,1% (19/234) of the patients were positive for antibodies reacting to Ca-FCS versus 4,7% (5/107) of controls (p=0,20). In addition 13,2% (31/234) of patients versus 2,8% (3/107) of controls were positive for antibodies reacting to Ca-Fib (p=0,003). Not all individuals harbored both reactivities and (39/234) 16,7% of patients and 8/107 (7,5%) of controls were positive for at least one anti-CarP antibody (p=0,028) (data not shown) and 11/234(4,7%) vs 0 of the controls (p=0,017) were positive for both anti-CarP reactivities.
Since the cohort of JIA patients consisted of different disease categories these were analyzed separately ( Figure 1 ). Anti-CarP antibodies were predominantly present in polyarticular IgM-RF positive patients (8/19, 421%) as compared to the other JIA categories (p<0.0001). This observation was made for both Ca-FCS and Ca-Fib as detecting antigens (Figure 1 ).
Together, these data indicate that the presence of anti-CarP-antibodies in JIA is mainly confined to polyarticular IgM-RF positive patient group. in ACPA and IgM-RF-negative children as 57,9% (11/19) of anti-CarP-positive children were negative for anti-CCP antibodies and 27,3% (3/11) were negative for IgM-RF. In total 9 JIA patients were positive for IgM-RF, anti-CCP and anti-CarP (Ca-FCS and/or Ca-Fib). All triple positive patients were part of the ABC register.
Correlation with clinical features
Disease duration at sample collection, ANA status or age (at onset or at sample collection) was not associated with the presence of anti-CarP-antibodies. In addition, in the group previously described by Albers [20] we did not find an association of anti-CarP positivity with disease activity measured by time-in-active-disease at the time of sampling. Within the ABC register cohort no association was found between the presence of anti-CarP antibodies and ACR-Pedi 30 response [23] or reaching inactive disease at 15 months after start of anti-TNF treatment. [24] The cross-sectional nature of this study comprising three cohorts did not allow further detailed clinical association studies.
Discussion
Here we report that anti-CarP antibodies, initially identified in samples of adult RA-patients, are also present in (categories of) JIA. The detection of anti-CarP antibodies, especially in the IgM-RF-positive JIA category, reflects the similarity between RA and polyarticular IgM-RF positive JIA. The presence of anti-CarP antibodies in anti-CCP-negative RA is associated with a more severe disease course as expressed by radiological damage. [15] In our analyses information on radiographic damage is currently not available. We did not observe an association between anti-CarP antibodies and time-in-active-disease or clinical response to anti-TNF therapy but this could be due to lack of power. Disease severity differed across the three studies, but in general a severely affected group was collected as represented by the high percentages of polyarticular JIA and the use of biologicals. Although the numbers are too small to draw conclusions we observed that the triple positive sera (IgM-RF, anti-CCP and anti-CarP) were all confined to the ABC group that represent severe cases.
One limitation of this study is the cross-sectional nature of the sera used. Although this contributed to a large sample size detailed analyses of the association between the presence of anti-CarP antibodies and clinical outcome were not possible, as patients were included at different follow-up times and clinical parameters were recorded differently in each study.
In conclusion, anti-CarP antibodies are not only present in RA patients, but are also detectable in patients with JIA. They are present predominantly in the polyarticular RFpositive JIA category in both anti-CCP-positive and negative patients. Studies dedicated to 
